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Azithromycin in healthy adults?
The paper by S. D. Putnam et al in Clinical Microbiology and
Infection [1], advocates the use of azithromycin as a
chemoprophylactic agent to reduce streptococcal colonization
among healthy adult male military recruits. Their conclusion
seems contrary to the prudent use of antibiotics, and stimulated
us to read the paper carefully.
We first realized that the paper is based on a study already
published [2], on which we would comment that statistical
inferences are appropriate only to test hypotheses set forward
before data are collected.
The main objection to the study is that it compares three
arms (azithromycin vs. benzathine penicillin G [BCG] vs.
controls), one of which is inappropriate, based on the phar-
macokinetcs. The idea that a single intramuscular injection of
1.2 mega units of BPG might affect the throat flora of people
living in close quarters, as assessed 63 days later, is biologically
unsound. To our knowledge, the long-term penicillin prophy-
laxis of streptococcal infections requires that BPG administra-
tion be repeated every 4–5 weeks. Also conceptually unsound is
the idea that streptococcal colonization of the upper airways
should be prevented in healthy adults, in the absence of
outbreaks.
To these general objections many others may be added, on
specific points.
The introductory statement on the antibiotic prophylaxis
of streptococcal infections might well have referred to standard
textbooks or to approved guidelines. The authors choose to
cite two papers with little bearing on the argument, one on
the prevention of perinatal group B streptococcal disease and
one on the prevention of streptococcal bacteremia in bone
marrow transplant recipients. As to the practice in military
populations, there is one self-reference [reference 4 in their
paper].
To substantiate the statement that ‘over the past few years
penicillin-tolerant and -resistant streptococcal strains have
emerged world wide. . . .’, they refer to a paper published in
1996, and they make no distinction between Streptococcus
pneumoniae, where the problem is real and S. pyogenes, for
which the statement is false. In addition, no mention is made
of the real emergence of macrolide resistances in S. pyogenes [3].
The alarming increase in the rate of respiratory disease in a
particular military population is stated to have occurred ‘over
the past few years’, but the reference (again a self-reference) is
to a paper of several years ago.
There is a contradiction in the statement that ‘these outbreaks
are well documented, but defined etiological information is
limited’.
The two further self-references in the introduction state that
BPG prophylaxis had proved not to reduce respiratory
morbidity during outbreaks, and put forward three hypotheses
to explain the finding – none of these has been taken into
account in the planning of the study at the basis of the paper. No
mention is made of the strong contrary evidence [4].
The study design is clearly the one reported elsewhere;
if not so, many details appear incongruous in the present
paper, which essentially deals with colonization prevalences,
to assess which it is wasteful to draw over 14 L of blood (or over
30 L [2]).
The study is said to have been completed ‘after 63 days of
training’; actually, 63 was the median period, and the subjects
were followed from less than 55 to over 100 days [2].
The microbiology section is at the same time un-informative
(oro- or naso-pharyngeal swabs?), redundant (incubation con-
ditions repeated four times) and lexically original (optochin-
positive?!).
The susceptibility testing section alludes to break points ‘used
in this study’, but does not state them; no harm, as no mention
of them is made anywhere else in the paper.
The statistical analysis section shows that the authors are
aware of the requirements for the validity of the chi-square test,
but they arbitrarily assume that they are met, when they are not:
all expected frequencies for S. pneumoniae carriage are < 5.
MIC means (arithmetic or geometric?) are said to have been
calculated, but none is reported.
In the results section, the authors state that the incomplete
follow-up was similar in the three arms. In fact, there is only
about 1 in 100 probability that the differences were due to
chance. Moreover, they attribute the drop outs to ‘training
attrition’, drug non-compliance and side-effects, without
giving a breakdown for the three arms. It is hard to envisage
drug non-compliance for the control group or, in fact, for the
BPG group, treated only once, ‘upon enrollment’. We are at a
loss to understand what training attrition means, but we doubt
that it may be increased by a single injection of BPG, so we
conclude that there were side-effects; but how could these
interrupt the completion of the study, which required no
further injections?
Of the 133 intervening cases of acute respiratory disease no
details are given, nor is it stated how the streptococcal etiology
was proved (if this is what the authors mean by ‘cases of . . . ’).
‘. . . the percentage distribution of S. pyogenes isolates among
the three intervention groups . . .’ is 4.5, 34.4 and 59.1, not
0.7%, 5.5% and 8.2%, which are the colonization frequencies in
the three groups.
Same objection for S. pneumoniae.
Regarding the slight upward shift of the MICs for S.
pneumoniae, the authors favor the hypothesis that it is an
aberration, or that it is due to unknown factors, and lightly
dismiss the idea that over 1.6 kg of azithromycin distributed in a
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closed population over a period of 3–5 months might have
exerted a selection pressure over the circulating strains.
In the discussion section, ‘access’ is probably misprinted for
‘assess’.
Comments on the rather low overall prevalence of
S. pyogenes, and on the extraordinarily low one of S. pneumoniae
– which cast doubts on the sensitivity of the isolation pro-
cedures – confusedly suggest, but do not admit, that the
statistical power of the study was simply not adequate to draw
conclusions.
Doubts also arise about the ‘point prevalence snapshots’, as
the periods of training did not start and finish at single time
points, given that the study was conducted ‘between November
1994 and March 1995’; the actual date of the isolations should
have been considered as a covariate.
The statement that the study was conducted in accordance
with official guidelines is a poor substitute for the one usually
required for clinical trials, and we remain with the disturbing
doubt: has each study subject given a written and truly informed
consent?
In conclusion, we much regret to see the official journal of
the European Society of Clinical Microbiology and Infection
accept as an Original Article a paper which is an untimely and
incompetent manipulation of data already published. Needless
to say, we would never advocate the mass use of azythromycin
(or any other drug) to reduce streptococcal colonization in
healthy adults.
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Response
We appreciate the authors’ criticisms of our paper [1], but we
wish to clarify some of their misunderstandings.
Our paper’s [2] focus was rather simple. Using data from a
previously published clinical trial [3], we sought to assess
changes in antimicrobial susceptibility levels of two common
respiratory pathogens (Streptococcus pyogenes and S. pneumoniae)
among US military personnel enrolled in a respiratory disease
chemoprophylaxis trial. Our findings, based upon limited data,
indicated that there was little or no change in the minimum
inhibitory concentrations (MICs) before and after the admin-
istration of the chemoprophylactic drugs.
We agree with Urbano and Urbano that using a single 1.2
million unit injection of benzathine penicillin G (BPG) injec-
tion is limited in its antimicrobial scope. We also recognize that
the prophylactic effect of BPG against S. pyogenes is expected to
protect an individual for only 2–4 weeks [4]. However, for more
than 40 years, the US Department of Defense has successfully
used mass BPG prophylaxis to prevent and control respiratory
infection epidemics among military trainees [5–9]. This protec-
tion has been broad, frequently exceeding the magnitude of that
which would be explained by the reduction of streptococcal
infections alone [10]. The protection has also been prolonged,
especially among US Army trainees, where a single dose of BPG
will often protect a cohort for up to 8 weeks [10]. Although not
well understood, the broad and persistent control is thought to
be due to the impact mass BPG prophylaxis has on endemic
respiratory pathogens in a training cohort as a whole. Such
cohorts experience little mixing with other cohorts and benefit
from a mass BPG influenced ‘herd protection’.
As several ‘outbreaks’ of respiratory disease had occurred
among US Marine trainees in Southern California in the late
1980s and early 1990s, the value of BPG interventions was
questionable, considering the mixed etiology of infecting agents
[11–13]. There was also concern that BGP prophylaxis might
eventually select for penicillin-resistant/tolerant S. pyogenes
strains and the US Department of Defense would be wise to
identify alternative therapies. In contrast to Urbano and
Urbano’s comments, we believe the literature suggests that
the threat of selecting for penicillin tolerance/resistance to be
very real [14–16]. We were seeking an alternative antibiotic
intervention with broad impact, for use in fast-moving respira-
tory epidemics. The aim of the original study [3] was to
compare the efficacy of azithromycin with the then routine
outbreak intervention of a single injection of BPG [9]. We
compared the interventions for their protection against a
number of respiratory pathogens.
We agree that the isolation procedure (throat swabs) for the
recovery of both strains was not the optimal method and
may have underestimated the true prevalence of both species
among our trainees. However, the same method was used for
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